By Jill Stein
Special to DG News
DENVER, CO — April 19, 2002 — The atypical antipsychotic quetiapine decreased frequency and severity of severe migraine, according to an open-label study reported here yesterday at the 54th Annual Meeting of the American Academy of Neurology.
Dr. Jan Brandes, of the Nashville Neuroscience Group in Nashville, Tennessee, tested quetiapine for migraine prophylaxis in 20 migraineurs over a three-month period. All participants in the trial had had minimal or no response to adequate preventive therapy in the past, and all had failed at least two prophylactic agents.
In Dr. Brandes' trial, quetiapine was started as adjunctive therapy at a daily dose of 25 mg and titrated to a maximum daily dose of 150 mg.
Results showed that seven of 17 patients, or 41 percent, reported a decrease in migraine frequency. Seven (41 percent) reported less severe attacks, nine (53 percent) reported shorter duration of attacks, and six (35 percent) reported a decreased Migraine Disability Assessment Questionnaire (MIDAS) score.
e-Med Tools
קצר קולע וממוקד
e-Med סמינרים
אי-מד תחקירים
Medscape Tools
Journal Club
מרכזי מידע ושירות
Facebook
מידע למפרסם
מאגר תרופות
מאגר אנשי המקצוע
אינדקס שימושי
חדשות משה"ב
eMed HealthClub
מחקרים קליניים
השאירו תגובה
רוצה להצטרף לדיון?תרגישו חופשי לתרום!